Home

Academic Achievements

Achievements of Boren Hospital

In the short span of seven years since its establishment,GoBroad Medical Institute of Hematology(Beijing Center),Beijing GoBroad Boren Hospital has achieved extraordinary accomplishments in the fields of immunotherapy and targeted therapy for hematological malignancies,as well as hematopoietic stem cell transplantation.It has published 43 high-level academic papers globally in authoritative journals in the field of hematology,such as JCO,Blood,and Leukemia,accumulating an impact factor of 424.21,and has presented its research findings over a hundred times at top international hematology conferences.Concurrently,the hospital has collaborated with peers in the industry to conduct a series of academic events,exploring high-quality medical services for patients.It has deeply cooperated with top domestic and international clinical practices,adopting and learning from the knowledge system,diagnostic and treatment processes,continuing education,patient education,management,and service philosophies of Mayo Clinic,the leading medical group in the United States,to elevate its own level.

Research Highlights

European Hematology Association

American Society of Hematology

American Society of Clinical Oncology

European Society for Blood and Marrow Transplantation

International Conference on Malignant Lymphoma

Asia Pacific Blood and Marrow Transplantation

About CAR-T

GoBroad Medical Institute of Hematology (Beijing Center),Beijing GoBroad Boren Hospital's CAR-T therapy is renowned for its comprehensive target selection, covering a wide range of hematologic malignancy targets, including single targets like CD19, CD20, CD22, CD7, CD5, BCMA, GPRC5D, as well as dual-target and triple-target CAR-T therapies. This offers targeted treatment plans for various leukemias, lymphomas, and myelomas. The comprehensiveness of these targets ensures the broad applicability and personalization of the treatment, bringing new hope to patients with different types of hematologic malignancies.

CAR-T therapy for adult leukemia
The GoBroad medical team is among the first in China to carry out immunotherapy,partnering with enterprises to pioneer the use of novel second-generation CD19-41BB-CAR-T cell therapy for treating refractory relapsed acute B lymphoblastic leukemia.Subsequently,the team co-developed multiple targeted CAR-T therapies for hematologic malignancies.Their research findings have been presented at internat…
Find out more
CAR-T Therapy for Adult Lymphoma and Multiple Myeloma
After five years of unremitting efforts,the adult lymphoma team has caught the first wave of the era from chemotherapy to targeted and cellular immunotherapy.Based on current technologies and advantages,with precise integrated diagnosis as the cornerstone,the team established the Lymphoma and Myeloma Research Institute,expanded the specialty transplantation repository,adhered to innovation,faced c…
Find out more
CAR-T Treatment for Pediatric Lymphoma
Under the leadership of Professor Zhang Yonghong,who has worked in pediatric hematologic oncology for over 30 years,the Pediatric Lymphoma Department was established in 2017 at Beijing GoBroad Boren Hospital.The team focuses on the treatment of refractory/recurrent pediatric lymphoma,continuously exploring the individual application of new methods such as CAR-T,targeted therapy,and precision treat…
Find out more
The Pediatric Hematologic Oncology Immunotherapy Team
Facing clinical challenges,continuously deepening CAR-T treatment for T-cell tumors:1.Autologous CD7 CAR-T for R/R T-ALL/LBL:One month after CAR-T infusion,the complete remission(CR)rate with MRD negativity was 85%.The median follow-up time was 9.2 months(range 0.3-24.0 months),among which,out of the 13 patients who underwent transplantation,MRD negative CR was achieved.No major infectious events …
Find out more